Can "artificial blood' live up to public billing?
作者信息
Cowart V S
出版信息
JAMA. 1982 Feb 26;247(8):1104-5.
PMID:7057595
Abstract
摘要
相似文献
1
Can "artificial blood' live up to public billing?“人造血液”能名副其实吗？
JAMA. 1982 Feb 26;247(8):1104-5.
2
Red cell substitutes: present status.
Indian J Pediatr. 1987 May-Jun;54(3):403-8. doi: 10.1007/BF02748927.
3
Polyhemoglobin and fluorocarbon as blood substitutes.
Biomater Artif Cells Artif Organs. 1987;15(2):333-6. doi: 10.3109/10731198709118534.
4
Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?携氧血液替代品（氟碳化合物和血红蛋白溶液）可预见的临床应用是什么？它们可能会对血液服务活动产生哪些影响？
Vox Sang. 1982 Feb;42(2):97-109. doi: 10.1159/000460856.
5
Clinical experience with Fluosol-DA (20%) in the United States.
Int Anesthesiol Clin. 1985 Spring;23(1):185-97. doi: 10.1097/00004311-198502310-00017.
6
The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study.
Surg Neurol. 1982 Jan;17(1):66-70. doi: 10.1016/0090-3019(82)90048-9.
7
Perfluorochemical emulsion oxygen transport fluids: a clinical review.
Annu Rev Med. 1985;36:309-13. doi: 10.1146/annurev.me.36.020185.001521.
8
Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.全氟碳化合物氟索-DA在冠状动脉血管成形术中的作用。
Am J Med Sci. 1994 Mar;307(3):218-21. doi: 10.1097/00000441-199403000-00009.
9
Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):1069. doi: 10.3109/10731199209119765.
10
Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog.
Bibl Haematol. 1981(47):54-69. doi: 10.1159/000402210.
引用本文的文献
1
Surgery in Jehovah's Witnesses.耶和华见证人的外科手术。
Can J Anaesth. 1989 Sep;36(5):578-85. doi: 10.1007/BF03005389.
Zotero 插件